CureVac (CVAC)
(Delayed Data from NSDQ)
$2.33 USD
+0.02 (0.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.33 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
CVAC 2.33 +0.02(0.87%)
Will CVAC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CVAC
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?
Company News for Jan 11, 2023
Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade
Other News for CVAC
CureVac price target lowered by $4 at UBS, here's why
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
CureVac just downgraded at Leerink, here's why